See the latest news and media coverage for Guard Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotech developing kidney disease therapies
guardtherapeutics.comLast updated
In short: Guard Therapeutics entered a conditional agreement for a reverse takeover with Disruptive Pharma after facing potential delisting from Nasdaq.
The companies will complete an issue-in-kind share exchange making Disruptive Pharma a subsidiary, with Disruptive shareholders holding ~55%. Valuation: Disruptive SEK61m, Guard SEK50m. EGM set 2026-07-20.
Nasdaq notes insufficient active operations, risking delisting by June 17, 2026. Company evaluates merger or reverse acquisition; may recommend delisting and liquidation if no deal.
Company identifies potential merger or reverse takeover counterparties and plans due diligence in Q2 2026. If no alternatives, delisting and liquidation may follow.
The review, exploring mergers or RTOs, progresses as planned and nears completion in Q1 2026. Significant interest exists, but liquidation is possible if no deal materializes.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...
Guard Therapeutics reports a result of minus 6.4 million kronor (minus 34.2) for the first quarter of 2026. Liquid funds at the end of...
The crisis-hit biotech company Guard Therapeutics risks being delisted from Nasdaq First North Growth Market.
Close Danske bank: This is why the Riksbank must panic-raise rates now. Susanne Spector, chief economist at Danske bank, was interviewed in Börsmorgon. The research company Guard Therapeutics has completed the overall exploratory work...
Track Guard Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.